Three New Therapies Approved for Multiple Myeloma
FDA approved three new drugs for relapsed multiple myeloma: daratumumab, ixazomib, and elotuzumab. Ixazomib, an oral proteasome inhibitor, and elotuzumab, a monoclonal antibody, showed improved progression-free survival in trials. Daratumumab demonstrated single-agent activity, offering new treatment options despite short remission durations.
Reference News
Three New Therapies Approved for Multiple Myeloma
FDA approved three new drugs for relapsed multiple myeloma: daratumumab, ixazomib, and elotuzumab. Ixazomib, an oral proteasome inhibitor, and elotuzumab, a monoclonal antibody, showed improved progression-free survival in trials. Daratumumab demonstrated single-agent activity, offering new treatment options despite short remission durations.